The 2026 Healthcare & Life Sciences Playbook
Frost & Sullivan Podcasts
As AI, genomics, and consumer-driven care all mature at once, which of these forces will actually move the needle for healthcare and life sciences in 2026, and which will quietly stall out?
In this episode of Frost & Sullivan's Growth Podcast, we explore the 2026 Healthcare & Life Sciences Playbook, examining what separates innovations that scale from those that stay stuck in pilot mode.
Healthcare and life sciences is shifting from experimentation to execution. AI is no longer scaling on novelty alone, it's scaling where it meets regulatory credibility, reimbursement pathways, and minimal clinical disruption. Meanwhile, multi-omics data is abundant, but the real competitive edge belongs to organizations that can query, reuse, and combine that data, not just collect it.
We also look at why interoperability has become a strategic differentiator rather than a technical afterthought, how value-based care is expanding into high-cost specialties like oncology and cardiology, and how consumerization is pushing care delivery toward at-home, anywhere-anytime models.
👉 What separates AI tools that scale from those that stall in pilot?
👉 Why is operationalizing multi-omics data more valuable than simply collecting it?
👉 How is value-based care reshaping decisions in high-cost specialties like oncology and cardiology?
Designed for healthcare executives, life sciences leaders, and innovation and strategy teams, this episode provides a strategic perspective on what will drive, and what could derail; growth across the industry in the upcoming months.
Explore related research: https://www.frost.com | https://store.frost.com
Connect with our team: hello@frost.com
Loading